- Home
- SEER vs CLLS Comparison
SEER vs CLLS Comparison
Compare SEER & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- CLLS
- Stock Information
- Founded
- SEER 2017
- CLLS 1999
- Country
- SEER United States
- CLLS France
- Employees
- SEER N/A
- CLLS N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- CLLS Health Care
- Exchange
- SEER Nasdaq
- CLLS Nasdaq
- Market Cap
- SEER 135.0M
- CLLS 148.1M
- IPO Year
- SEER 2020
- CLLS 2007
- Fundamental
- Price
- SEER $2.27
- CLLS $1.63
- Analyst Decision
- SEER Hold
- CLLS Buy
- Analyst Count
- SEER 1
- CLLS 3
- Target Price
- SEER $3.00
- CLLS $7.00
- AVG Volume (30 Days)
- SEER 150.7K
- CLLS 221.4K
- Earning Date
- SEER 02-27-2025
- CLLS 11-04-2024
- Dividend Yield
- SEER N/A
- CLLS N/A
- EPS Growth
- SEER N/A
- CLLS N/A
- EPS
- SEER N/A
- CLLS N/A
- Revenue
- SEER $14,608,000.00
- CLLS $36,042,000.00
- Revenue This Year
- SEER N/A
- CLLS $387.77
- Revenue Next Year
- SEER $34.78
- CLLS $11.14
- P/E Ratio
- SEER N/A
- CLLS N/A
- Revenue Growth
- SEER N/A
- CLLS 46.96
- 52 Week Low
- SEER $1.51
- CLLS $1.41
- 52 Week High
- SEER $2.63
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- SEER 41.78
- CLLS 44.81
- Support Level
- SEER $2.29
- CLLS $1.45
- Resistance Level
- SEER $2.39
- CLLS $1.65
- Average True Range (ATR)
- SEER 0.08
- CLLS 0.12
- MACD
- SEER -0.01
- CLLS 0.00
- Stochastic Oscillator
- SEER 14.42
- CLLS 31.43
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.